Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. J Comp Eff Res 2014 Mar;3(2):135-44

Date

03/22/2014

Pubmed ID

24645687

Pubmed Central ID

PMC4036637

DOI

10.2217/cer.13.95

Scopus ID

2-s2.0-84897837351 (requires institutional sign-in at Scopus site)   16 Citations

Abstract

BACKGROUND: BMT CTN 1101 is a Phase III randomized controlled trial evaluating the comparative effectiveness of double unrelated umbilical cord blood (dUCB) versus HLA-haploidentical related donor bone marrow (haplo-BM) donor cell sources for blood or bone marrow transplantation (BMT) in patients with hematologic malignancies. Herein, we present the rationale, design and methods of the first cost-effectiveness analysis to be conducted alongside a BMT trial.

METHODS: Consenting patients will provide health insurance information to allow calculation of direct medical costs from reimbursement records, and will provide out-of-pocket costs, time costs and health-related quality of life measures through an online survey. These outcomes will inform a cost-effectiveness analysis comparing dUCB and haplo-BM donor cell sources from patient, payer and societal perspectives.

CONCLUSION: Novel approaches may significantly change the cost, outcomes or availability of BMT. The results of this analysis will be the first to provide a comprehensive evaluation of the comparative effectiveness of these approaches from multiple perspectives.

Author List

Roth JA, Bensink ME, O'Donnell PV, Fuchs EJ, Eapen M, Ramsey SD

Author

Mary Eapen MBBS, DCh, MRCPI, MS Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adolescent
Adult
Aged
Bone Marrow Transplantation
Comparative Effectiveness Research
Cord Blood Stem Cell Transplantation
Cost-Benefit Analysis
Female
Health Care Costs
Health Expenditures
Hematologic Neoplasms
Humans
Male
Middle Aged
Quality of Life
Young Adult